Lilly and Novo Nordisk oral obesity drugs take top billing at JP Morgan
Of the billions that have been made and lost by investors in big pharma in the last two or three years, a significant chunk has involved the two biggest players in the burgeoning obesity field—Eli Lilly (NYSE: LLY) and Novo Nordisk (NOV: N).
These two companies have led the way with their GLP-1 receptor agonists, Lilly’s Mounjaro (tirzepatide) and Novo Nordisk’s Ozempic (semaglutide), with perceptions that the former was winning the battle last year a factor in the Danish company’s shares slipping in value by nearly 50% in 2025.
So, it is perhaps no surprise that bosses from Lilly and Novo Nordisk have taken center stage at this year’s JP Morgan Healthcare Conference in San Francisco, particularly in relation to the launches of oral Wegovy (semaglutide) and Lilly's small molecule GLP-1 agonist orforglipron.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze